GT Biopharma Files 8-K on Agreements and Personnel Changes
Ticker: GTBP · Form: 8-K · Filed: Jun 11, 2025 · CIK: 109657
Sentiment: neutral
Topics: material-agreement, management-change, filing
TL;DR
GT Biopharma 8-K: New deals, exec changes, and financials filed June 11.
AI Summary
GT Biopharma, Inc. filed an 8-K on June 11, 2025, reporting on a material definitive agreement, the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the report date being June 10, 2025.
Why It Matters
This 8-K filing indicates significant corporate actions, including potential new agreements and changes in leadership or compensation, which could impact the company's strategic direction and operational stability.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and changes in officers/directors, which can introduce uncertainty or signal strategic shifts.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- June 10, 2025 (date) — Report Date
- June 11, 2025 (date) — Filing Date
FAQ
What is the nature of the material definitive agreement reported by GT Biopharma?
The filing does not specify the details of the material definitive agreement, only that it is an 'Entry into a Material Definitive Agreement'.
Who are the directors or officers that have departed or been elected/appointed?
The filing lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item, but does not name the individuals involved.
What specific compensatory arrangements are detailed in the filing?
The filing mentions 'Compensatory Arrangements of Certain Officers' but does not provide specific details within the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing indicates 'Financial Statements and Exhibits' are included, but the specific content is not detailed in the provided header information.
What was GT Biopharma's former name and when did it change?
GT Biopharma, Inc. was formerly known as OXIS INTERNATIONAL INC, with a name change date of 19940916. It was also formerly known as DDI PHARMACEUTICALS INC (name change 19920703) and DIAGNOSTIC DATA INC /DE/ (name change 19850312).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 11, 2025 regarding GT Biopharma, Inc. (GTBP).